Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview:
- Global Oncolytic Virus Immunotherapy Therapy Market Overview
- Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028
- Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials
- Patent Information On More Than 60 Therapies in Clinical Trials
- IMLYGIC, Oncorine, Delytact: Availability, Dosage & Price Analysis
- Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment
- Oncolytic Virus Immunotherapy Application By 10 Cancer
- Recent Strategic Partnerships, Collaborations, Mergers & Acquisitions
Donload Report: https://www.kuickresearch.com/report-oncolytics-virus-immunotherapy-oncolytics–therapy-clinical-trials
Oncolytic virotherapy has emerged as one of the newest treatment options in the recent years to gain traction from researchers and scientists, who are anxiously looking for cutting-edge methods for the treatment and management of cancer. This has been especially helpful because the conventionally used treatment methods show little or no benefits in patients with metastatic cancer. The prospect of oncolytic viruses has been explored in many forms of cancer and has returned positive results from several clinical trials, indicating the potential for the therapy in the future.
While oncolytic viruses were first studied in the early 1960s, their entry into the clinical pipeline did not happen until the late 1990s, with China’s Shanghai Sunway Biotech taking lead and coming up with Oncorine in 1999 for the treatment of head and neck cancer. Further, it was approved 6 years later in 2005 by the NMPA, which granted market access to the drug. Other than Oncorine, two more oncolytic viruses have received marketing approval – Imlygic and Delytact. However, Imlygic (Amgen) being the only oncolytic virus to have gained both FDA and EMA approval, contributes maximum to the overall market share of oncolytic virotherapy because of its availability in more number of countries compared to the other two, which have been approved in only select few regions.
Even though the hype created for Imlygic did not translate into revenues for Amgen, several clinical trials are now accessing the combination of Imlygic with other immunotherapies in order to push Imlygic as a mainstream treatment for melanoma. This includes combination with chemotherapy, monoclonal antibodies, and conventional treatment methods. The approval of such combinations is expected to bring Imlygic back into the limelight for melanoma treatment.
These clinical trials involving the combination of Imlygic with other treatment modalities is being seen with investigational drugs as well, which several early stage clinical trials evaluating the combination of OVs with other treatments. Combination therapies, in particular, have demonstrated some of the best response rates in patients over a number of years and have risen as the promising treatment procedure for cancer treatment. Therefore the approval of drugs combination is expected to increase the market share of oncolytic viruses in the coming years.
Based on results from several clinical trials, it is evident that therapies with oncolytic viruses hold the key towards a successful cancer treatment and management strategy. It is thus essential to improve our understanding of the mechanisms of action and the interaction of the viruses with the immune system as a result of which an immune response in generated. The approval and success of OVs in the market can provide further practical treatment options of the treatment of several forms of cancer, enhanced by their combination with other forms of treatment. Currently several investigational oncolytic viruses are in clinical trials and some more are in the development pipeline, which highlights the potential they hold in cancer treatment. With several major players, like Merck through its acquisition of Viralytics, slowly entering the market for oncolytic viruses, the domain is expected to gain more attention in the coming years.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com
